文献速递银屑病与炎症性皮肤病

司库奇尤单抗对比依那西普持续改善银屑病患者报告结局达1年

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
PubMed 文献 · J Am Acad Dermatol · 2017-01-10

两项III期随机安慰剂对照试验共纳入1470例中重度银屑病患者,比较司库奇尤单抗与依那西普对DLQI的影响。司库奇尤单抗组第24周DLQI 0/1应答率显著更高,中位应答时间更短(12 vs 24周,P < .01),且多数患者应答持续至第52周。

要点

  • 司库奇尤单抗第24周DLQI 0/1应答率显著高于依那西普。
  • 司库奇尤单抗中位DLQI 0/1应答时间为12周,依那西普为24周。
  • 多数司库奇尤单抗治疗患者DLQI 0/1应答持续至第52周。

核心结论

  • 司库奇尤单抗治疗在52周内比依那西普提供更快、更持续的生活质量改善,与更好的临床应答一致。

研究设计与样本

  • 两项III期随机安慰剂对照临床试验,共1470例中重度银屑病患者,1144例接受司库奇尤单抗,326例接受依那西普。

主要发现

  • 司库奇尤单抗组第24周DLQI 0/1应答率显著高于依那西普组。
  • 司库奇尤单抗组中位DLQI 0/1应答时间显著短于依那西普组(12 vs 24周;P < .01)。
  • 多数司库奇尤单抗治疗患者在24周达到DLQI 0/1应答并持续至52周,同时PASI总分应答改善90%至100%。

关键数值与推荐

  • DLQI 0/1应答定义为DLQI评分0或1。
  • 中位DLQI 0/1应答时间:司库奇尤单抗12周 vs 依那西普24周(P < .01)。

临床怎么用

  • 对于中重度银屑病患者,司库奇尤单抗可更快改善健康相关生活质量并维持至1年。

局限性

  • 维持期安慰剂比较受限,因第12周重新随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept. RESULTS: Of 1470 subjects, 1144 received secukinumab and 326 received etanercept. DLQI score 0/1 response rates were significantly higher for secukinumab than for etanercept at week 24. The median time to DLQI score 0/1 response was significantly shorter for secukinumab versus etanercept (12 vs 24 weeks; P < .01). The majority of secukinumab-treated subjects achieved DLQI score 0/1 response at week 24 and sustained it through week 52 along with a 90% to 100% reduction in the Psoriasis Area and Severity Index total score response. LIMITATIONS: Placebo comparisons are limited during the maintenance period because of rerandomization at week 12. CONCLUSION: Secukinumab treatment provided faster and greater sustained improvements in quality of life than etanercept over 52 weeks, consistent with greater clinical response.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Gottlieb AB, Sherif B, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017. PMID: 28087133. doi:10.1016/j.jaad.2016.11.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。